IONS' shares fell after announcing the pricing of its secondary issue of shares, which were at a 12% discount to the previous closing price.

The analyst highlighted the early adoption of key Novartis products, such as Kisqali, Scemblix, and Pluvicto, as significant drivers of the stock's recent momentum. Moreover, the anticipated positive ...

such as the expected pelacarsen readout. The reaffirmed Market Perform rating and price target suggest a steady outlook for Novartis shares according to BMO Capital's analysis. In other recent ...

Analyst Etzer Darout of BMO Capital maintained a Hold rating on Novartis (NVS – Research Report), retaining the price target of $118.00.

In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against the other stocks on Jim Cramer’s radar. Jim Cramer often reflects on how he would reform the American ...

While Novartis has a number of promising pipeline products—such as Cosentyx, pelacarsen, ianalumab, and Pluvicto—key data releases and potential approvals for these drugs are not expected to ...

Novartis AG (NYSE:NVS) is a Swiss multinational pharmaceutical company that specializes in innovative drugs across key areas like oncology, rare diseases, neuroscience, and cardio-metabolic ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

For women, levels of LDL cholesterol, high-sensitivity C-reactive protein (hs-CRP), and lipoprotein(a) at middle age are strongly associated with cardiovascular events over the next three decades, ...

Lindy Biosciences has announced an exclusive global licensing agreement and strategic collaboration with Novartis Pharma AG. The deal centres on Lindy’s microglassification technology, which ...